Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;95(6):1222-1230.
doi: 10.1016/j.mayocp.2020.03.026. Epub 2020 Apr 4.

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019

Fabian Sanchis-Gomar  1 , Carl J Lavie  2 , Carme Perez-Quilis  3 , Brandon M Henry  4 , Giuseppe Lippi  5
Affiliations
Review

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019

Fabian Sanchis-Gomar et al. Mayo Clin Proc. 2020 Jun.

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, is being defined as the worst pandemic disease of modern times. Several professional health organizations have published position papers stating that there is no evidence to change the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in the management of elevated blood pressure in the context of avoiding or treating COVID-19 infection. In this article, we review the evidence on the relationship between the renin-angiotensin-aldosterone system and COVID-19 infection. In agreement with current guidelines, patients with hypertension should continue taking antihypertensive medications as prescribed without interruption. Because ACEIs and ARBs are also used to retard the progression of chronic kidney disease, we suggest that these recommendations also apply to the use of these agents in chronic kidney disease. No differences generally exist between ARBs and ACEIs in terms of efficacy in decreasing blood pressure and improving other outcomes, such as all-cause mortality, cardiovascular mortality, myocardial infarction, heart failure, stroke, and end-stage renal disease. The ACEIs are associated with cough secondary to accumulation of bradykinin and angioedema, and withdrawal rates due to adverse events are lower with ARBs. Given their equal efficacy but fewer adverse events, ARBs could potentially be a more favorable treatment option in patients with COVID-19 at higher risk for severe forms of disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Localization of angiotensin-converting enzyme 2 protein in human organs and tissues. SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
Figure 2
Figure 2
Scheme of the renin-angiotensin-aldosterone system and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection mechanism. ACE = angiotensin-converting enzyme; Ang = angiotensin; ARB = angiotensin receptor blocker; AT1R = angiotensin II type 1 receptor; MasR = Mas receptor; TMPRSS2 = type II transmembrane serine proteases.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shah A., Kashyap R., Tosh P., Sampathkumar P., O’Horo J.C. Guide to understanding the 2019 novel coronavirus [published online February 28, 2020] https://doi.org/10.1016/j.mayocp.2020.02.003 Mayo Clin Proc. - DOI - PMC - PubMed
    1. Mahase E. Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction [published online March 12, 2020] https://doi.org/10.1136/bmj.m1036 BMJ. - DOI - PubMed
    1. Lippi G., Sanchis-Gomar F., Henry B.M. Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. https://doi.org/10.21037/atm.2020.03.157 Ann Transl Med. - DOI - PMC - PubMed
    1. World Health Organization Coronavirus disease 2019 (COVID-19) situation report–62. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio... Published March 22, 2020. Accessed March 25, 2020.
    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention [published online February 24, 2020] https://doi.org/10.1001/jama.2020.2648 JAMA. - DOI - PubMed

Publication types

MeSH terms

Substances